Insulin Centennial: Milestones influencing the development of insulin preparations since 1922
出版年份 2021 全文链接
标题
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 24, Issue S1, Pages 27-42
出版商
Wiley
发表日期
2021-10-28
DOI
10.1111/dom.14587
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Improved Postprandial Glucose Control With Ultra Rapid Lispro Versus Lispro With Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes: PRONTO‐Pump ‐2
- (2021) Mark Warren et al. DIABETES OBESITY & METABOLISM
- One Hundred Years of Insulin for Some
- (2021) Amy Moran-Thomas NEW ENGLAND JOURNAL OF MEDICINE
- The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications
- (2020) David R. Owens et al. DIABETES OBESITY & METABOLISM
- Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
- (2020) Athena Philis-Tsimikas et al. DIABETOLOGIA
- Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study
- (2020) Leslie Klaff et al. DIABETES OBESITY & METABOLISM
- Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs
- (2020) Ulrich Werner et al. DIABETES OBESITY & METABOLISM
- Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
- (2020) Julio Rosenstock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of fast‐acting insulin aspart in insulin pump therapy in clinical practice
- (2019) Mark Evans et al. DIABETES OBESITY & METABOLISM
- Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences
- (2019) Hanne Haahr et al. CLINICAL PHARMACOKINETICS
- Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study
- (2019) Alice Cheng et al. DIABETES OBESITY & METABOLISM
- More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
- (2018) Julio Rosenstock et al. DIABETES CARE
- Concentrated Insulins: History and Critical Reappraisal
- (2018) Lutz Heinemann et al. Journal of Diabetes
- Glycaemic variability in diabetes: clinical and therapeutic implications
- (2018) Antonio Ceriello et al. Lancet Diabetes & Endocrinology
- Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes
- (2018) Francesca Porcellati et al. DIABETES CARE
- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
- (2017) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection
- (2015) Paola Lucidi et al. DIABETES CARE
- Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
- (2015) Svend Havelund et al. PHARMACEUTICAL RESEARCH
- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
- (2014) Hanne Haahr et al. CLINICAL PHARMACOKINETICS
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions
- (2014) D. M. Nathan et al. DIABETES
- New Insulin Glargine 300 units{middle dot}mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 units{middle dot}mL-1
- (2014) R. H. A. Becker et al. DIABETES CARE
- The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
- (2014) Rolf Hilgenfeld et al. DRUGS
- A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review
- (2013) B. M. Frier et al. DIABETES OBESITY & METABOLISM
- Ligand-Controlled Assembly of Hexamers, Dihexamers, and Linear Multihexamer Structures by the Engineered Acylated Insulin Degludec
- (2012) Dorte B. Steensgaard et al. BIOCHEMISTRY
- The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences
- (2012) P. D. Home DIABETES OBESITY & METABOLISM
- Insulin's discovery: New insights on its ninetieth birthday
- (2012) Jesse Roth et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Alan J Garber et al. LANCET
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Simon Heller et al. LANCET
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
- (2011) F. Porcellati et al. DIABETES CARE
- Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study
- (2011) P. Lucidi et al. DIABETES CARE
- Insulin X10 revisited: a super-mitogenic insulin analogue
- (2011) B. F. Hansen et al. DIABETOLOGIA
- Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target
- (2010) A. Ceriello DIABETES CARE
- Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor
- (2010) A. R. Sørensen et al. DIABETES OBESITY & METABOLISM
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETOLOGIA
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More